研究室について

Home > 研究室について

研究室メンバー

伊東 伸朗

難治性骨疾患治療開発講座　特任准教授／骨粗鬆症センター　副センター長

専門医/学会委員

認定内科医、総合内科専門医、内科学会指導医　　　　　　　　　　　　　　　　　

内分泌代謝科専門医、内分泌代謝科指導医、日本内分泌学会評議員、糖尿病専門医、糖尿病学会研修指導医、臨床遺伝専門医、日本骨粗鬆症学会認定医、日本骨粗鬆症学会評議員、日本骨代謝学会評議員/将来構想委員会委員/Young Investigator Committee、国際筋骨格学会 (IFMRS) Future Global Leaders Committee、米国内分泌学会会員、米国骨代謝学会(ASBMR)会員、European Calcified Tissue Society(ECTS)会員

受賞/奨学金
2006年 第24回 日本骨代謝学会 IOF-ANZBMS Travel Award
2007年 第20回 内科学会奨励賞
2009年 住友生命社会福祉事業団　海外医学研究助成金
2010年 上原記念生命科学財団 ポストドクトラルフェローシップ
2021年 INTERNATIONAL AWARD for publishing Excellence in CALCIFIED TISSUE INTERNATIONAL &　MUSCULOSKELETAL RESEARCH
2023年 日本骨代謝学会フロンティア研究者助成　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　2024年 日本骨代謝学会学術賞

詳しくはこちら

加藤 創生　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　

留学中　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　Associate Research Scientist in Pathology, Yale School of Medicine 　　　　　　Braddock Lab Members < Braddock Lab (yale.edu)　　　　　　　　　　　　　　　　　　　　　　　　　

専門医
内科学会認定医、内分泌代謝科専門医、糖尿病専門医　　　　　　　　　　　　　　

その他所属学会
日本骨代謝学会会員、日本人類遺伝学会会員

受賞歴 受賞/奨学金
2021年 日本骨代謝学会優秀演題賞
2021年 日本骨代謝学会 ECTS Travel Award
2021年 日本骨代謝学会 ANZBMS Travel Award
2022年  第24回　日本骨粗鬆症学会　優秀ポスター賞
2022年  国際医学研究振興財団  海外留学助成(辞退)
2022年 内藤記念科学振興財団　海外留学助成金(辞退)
2022年  中富健康科学振興財団　留学助成金(辞退)
2023年  日本学術振興会　海外特別研究員
2023年 ECTS EAST-MEETS-WEST Award

日髙 尚子

大学院生

出身は福岡県です。好きな食べ物は高菜漬けです

専門医
内科学会認定医、内分泌代謝科専門医　　　　　　　　　　　　　　　　　　　　　

その他所属学会
骨代謝学会会員

受賞歴
2015年　第112回日本内科学会総会医学生・研修医部門優秀演題賞
2022年　第39回 日本骨代謝学会優秀演題賞

星野 良朋

大学院生

専門医
内科学会認定医、内分泌代謝科専門医　　　　　　　　　　　　　　　　　　　　　

その他所属学会
日本骨代謝学会

受賞歴
2021年　第672回 日本内科学会関東地方会指導医賞
2021年　東大病院優秀指導医賞
2023年　第96回日本内分泌学会学術総会「愛・内分泌」賞（優秀演題賞）　　　　　　　　　　　　　　　　2024年　第34回臨床内分泌代謝Update ポスター発表優秀発表賞

木村 聡一郎

大学院生

趣味　音楽鑑賞

専門医
内科学会認定内科専門医　　　　　　　　　　　　　　　　　　　　　　　　　　　

その他所属学会
日本内分泌学会、日本糖尿病学会、日本間脳下垂体腫瘍学会、日本骨代謝学会、日本骨粗鬆症学会

受賞歴
2023年　日本骨代謝学会 ANZBMS Travel Award

洲之内 尭

大学院生

趣味　登山、麻雀

専門医
内科学会認定内科専門医 　　　　　　　　　　　　　　　　　　　　　　　　　　　

その他所属学会
日本内分泌学会、日本糖尿病学会、日本骨代謝学会

渡部 創

大学院生 （老年病科：骨粗鬆症センターでの合同プロジェクト）

趣味　ボウリング、DIY

専門医
内科学会認定内科専門医　　　　　　　　　　　　　　　　　　　　　　　　　　　

その他所属学会
日本糖尿病学会、日本内分泌学会、日本老年医学会、日本骨粗鬆症学会、日本骨代謝学会

受賞歴
2023年　第96回日本内分泌学会学術総会「愛・内分泌」賞（優秀演題賞）　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　

入江 航生

大学院生

趣味　ジャグリング、動画鑑賞

所属学会
日本内科学会、日本内分泌学会、日本糖尿病学会、日本骨代謝学会　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　

尾崎 知子

技術補佐員

実験補助と事務作業を行っています

研究実績

  • Kato H, Ishihara Y, Ohata Y, Irie K, Watanabe S, Kimura S, Hoshino Y, Hidaka N, Kinoshita Y, Taniguchi Y, Kobayashi H, Braddock DT, Kubota T, Ozono K, Nangaku M, Makita N, Ito N. Effect of Mutation Type on Ectopic Ossification Among Adult Patients With X-Linked Hypophosphatemia. J Endocr Soc. 2024 Oct 22;8(12):bvae184. doi: 10.1210/jendso/bvae184. PMID: 39498416; PMCID: PMC11532897.
  • Namba N, Ito N, Michigami T, Kang HG, Kubota T, Miyazaki O, Shintani A, Kabata D, Nishida Y, Fukumoto S, Ozono K. Impact of X-linked hypophosphatemic rickets/osteomalacia on health and quality of life: baseline data from the SUNFLOWER longitudinal, observational cohort study. JBMR Plus. 2024 Sep 10;8(11):ziae118. doi: 10.1093/jbmrpl/ziae118. PMID: 39399158; PMCID: PMC11470975.
  • Michigami T, Kang HG, Namba N, Ito N, Kubota T, Shintani A, Kabata D, Kanematsu M, Nishida Y, Fukumoto S, Ozono K. Burosumab treatment of X-linked hypophosphatemia patients: interim analysis of the SUNFLOWER longitudinal, observational cohort study. JBMR Plus. 2024 Jun 10;8(8):ziae079. doi: 10.1093/jbmrpl/ziae079. PMID: 39015507; PMCID: PMC11250265.
  • Kimura S, Sunouchi T, Watanabe S, Hoshino Y, Hidaka N, Kato H, Takeda S, Nangaku M, Makita N, Azuma K, Kojima T, Matsubara T, Saito T, Ito N. Latent metabolic bone disease, skeletal dysplasia and other conditions related to low bone formation among 38 patients with subtrochanteric femoral fractures: a retrospective observational study. Osteoporos Int. 2024 Jul 1. doi: 10.1007/s00198-024-07168-4. Epub ahead of print. PMID: 38951164.
  • Hidaka N, Inoue K, Kato H, Hoshino Y, Koga M, Kinoshita Y, Takashi Y, Makita N, Fukumoto S, Nangaku M, Ito N. FGF-23, Left Ventricular Hypertrophy, and Mortality in Patients With CKD: A Revisit With Mediation Analysis. JACC Adv. 2023 Dec 9;3(1):100747. doi: 10.1016/j.jacadv.2023.100747. PMID: 38939808; PMCID: PMC11198284.
  • Kato H, Kitamoto T, Kimura S, Sunouchi T, Hoshino Y, Hidaka N, Tsurutani Y, Ito N, Makita N, Nishikawa T, Nangaku M, Inoue K. Cardiovascular Outcomes of KCNJ5 mutated Aldosterone-Producing Adenoma: A Systematic Review. Endocr Pract. 2024 Apr 22:S1530-891X(24)00497-X. doi: 10.1016/j.eprac.2024.04.007. Epub ahead of print. PMID: 38657793.
  • Tanaka Y, Soen S, Hirata S, Okada Y, Fujiwara S, Tanaka I, Kitajima Y, Kubota T, Ebina K, Takashi Y, Inoue R, Yamauchi M, Okubo N, Ueno M, Ohata Y, Ito N, Ozono K, Nakayama H, Terauchi M, Tanaka S, Fukumoto S. The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Metab. 2024 Mar 28. doi: 10.1007/s00774-024-01502-w. Epub ahead of print. PMID: 38538869.
  • Tanaka H, Tamura M, Muto M, Kinoshita Y, Ito N, Oka A, Kitanaka S. A novel pathogenic variant in fibroblast growth factor 23 outside the furin-recognizing RXXR motif in an autosomal dominant hypophosphatemic rickets patient. Horm Res Paediatr. 2024 Mar 15. doi: 10.1159/000538388. Epub ahead of print. PMID: 38493780.
  • Ito N, Hidaka N, Kato H. Acquired Forms of Fibroblast Growth Factor 23-Related Hypophosphatemic Osteomalacia. Endocrinol Metab (Seoul). 2024 Mar 11. doi: 10.3803/EnM.2023.1908. Epub ahead of print. PMID: 38467164.
  • Okajima K, Kobayashi H, Ito N, Kato H, Ishibashi Y, Zhang L, Tsuda Y, Tanaka S. Extended curettage for tumour-induced osteomalacia in the bone. Jpn J Clin Oncol. 2024 Jan 23:hyad180. doi: 10.1093/jjco/hyad180. Epub ahead of print. PMID: 38266040.
  • Tsuda Y, Yasunaga Y, Abe M, Hoshi K, Ito N, Kondo K, Okajima K, Zhang L, Kato H, Hidaka N, Tanaka S, Kobayashi H. Surgical and biochemical outcomes of phosphaturic mesenchymal tumors causing tumor-induced osteomalacia in the head and neck region. Oral and Maxillofacial Surgery Cases. 2023; 9 (4):100335. doi.org/10.1016/j.omsc.2023.100335.
  • Hidaka N, Murata H, Tachikawa K, Osaki K, Sekiyama T, Kinoshita Y, Kato H, Hoshino Y, Kimura S, Sunouchi T, Watanabe S, Nangaku M, Makita N, Michigami T, Ito N. The Effect of Asfotase Alfa on Plasma and Urine Pyrophosphate Levels and Pseudofractures in a Patient With Adult-Onset Hypophosphatasia. JBMR Plus. 2023 Nov 20;7(12):e10842. doi: 10.1002/jbm4.10842. PMID: 38130758; PMCID: PMC10731098.
  • Ito N, Hidaka N, Kato H. The pathophysiology of hypophosphatemia. Best Pract Res Clin Endocrinol Metab. 2023 Nov 30:101851. doi: 10.1016/j.beem.2023.101851. Epub ahead of print. PMID: 38087658.
  • Qian C, Ito N, Tsuji K, Sato S, Kikuchi K, Yoshii T, Miyata T, Asou Y. A PAI-1 antagonist ameliorates hypophosphatemia in the Hyp vitamin D-resistant rickets model mouse. FEBS Open Bio. 2023 Dec 5. doi: 10.1002/2211-5463.13745. Epub ahead of print. PMID: 38050660.
  • Arima T, Sugimoto K, Taniwaki T, Maeda K, Shibata Y, Tateyama M, Karasugi T, Tokunaga T, Sueyoshi T, Hisanaga S, Masuda T, Uehara Y, Yugami M, Matsushita K, Yonemitsu R, Kawakami J, Yoshimura N, Tanimura S, Kato H, Ito N, Inoue K, Bando K, Nakamura T, Miyamoto T. Cartilage tissues regulate systemic aging via ectonucleotide pyrophosphatase/phosphodiesterase 1 in mice. J Biol Chem. 2023 Nov 30:105512. doi: 10.1016/j.jbc.2023.105512. Epub ahead of print. PMID: 38042486.
  • Arai M, Ochi H, Sunamura S, Ito N, Nangaku M, Takeda S, Sato S. A Novel Long Noncoding RNA in Osteocytes Regulates Bone Formation through the Wnt/β-Catenin Signaling Pathway. Int J Mol Sci. 2023 Sep 4;24(17):13633. doi: 10.3390/ijms241713633. PMID: 37686441.
  • Kato H, Braddock DT, Ito N. Genetics of Diffuse Idiopathic Skeletal Hyperostosis and Ossification of the Spinal Ligaments. Curr Osteoporos Rep. 2023 Aug 2. doi: 10.1007/s11914-023-00814-6. Epub ahead of print. PMID: 37530996.
  • Kato H, Kimura S, Taguchi M, Sunouchi T, Hoshino Y, Hidaka N, Edvige Foligno N, Koga M, Manaka K, Tamiya H, Kawakami M, Kage H, Yasunaga Y, Nangaku M, Makita N, Ito N. FGF23-related hypophosphatemia in a patient with small cell lung cancer: a case report and literature review. Endocr J. 2023 Jul 20. doi: 10.1507/endocrj.EJ23-0086. Epub ahead of print. PMID: 37468265.
  • Hoshino Y, Manaka K, Sato J, Asatsuma Y, Horikoshi H, Takeuchi M, Ito N, Fujita M, Yasunaga M, Matsuda K, Honda A, Maki H, Masamoto Y, Kurokawa M, Nangaku M, Makita N. Recurrent bilateral adrenal infarction with myelodysplastic/myeloproliferative neoplasm-unclassifiable (MDS/MPN-U): a case report. BMC Endocr Disord. 2023 Jun 5;23(1):128. doi: 10.1186/s12902-023-01384-5. PMID: 37277771.
  • Kobayashi H, Ito N, Nakai Y, Katoh H, Okajima K, Zhang L, Tsuda Y, Tanaka S. Patterns of symptoms and insufficiency fractures in patients with tumour-induced osteomalacia. Bone Joint J. 2023 May 1;105-B(5):568-574. doi: 10.1302/0301-620X.105B5.BJJ-2022-1206.R2. PMID: 37121579.
  • Kato H, Miyazaki H, Kimura T, Hoshino Y, Hidaka N, Koga M, Nangaku M, Makita N, Ito N. Clinical performance of a new intact FGF23 immunoassay in healthy individuals and patients with chronic hypophosphatemia. Bone Rep. 2023 Feb 2;18:101659. doi: 10.1016/j.bonr.2023.101659. PMID: 36817167; PMCID: PMC9932357.
  • Ramos P, Larson B, Ashrafzadeh-Kian S, Ito N, Kato H, Bornhorst JA, Algeciras-Schimnich A. Intact Fibroblast Growth Factor 23 (iFGF23) Concentrations in Hypophosphatemic Disorders. Endocr Pract. 2023 Jan 7:S1530-891X(23)00002-2. doi: 10.1016/j.eprac.2023.01.003. Epub ahead of print. PMID: 36627024.
  • Kato H, Koga M, Kinoshita Y, Hidaka N, Hoshino Y, Takashi Y, Arai M, Kobayashi H, Katsura M, Nakamoto Y, Makise N, Ushiku T, Hoshi K, Nangaku M, Makita N, Fukumoto S, Ito N. Utility of Multimodality Approach Including Systemic FGF23 Venous Sampling in Localizing Phosphaturic Mesenchymal Tumors. J Endocr Soc. 2022 Nov 24;7(2):bvac181. doi: 10.1210/jendso/bvac181. PMID: 36540156; PMCID: PMC9757682.
  • Kato H, Okawa R, Ogasawara T, Hoshino Y, Hidaka N, Koga M, Kinoshita Y, Kobayashi H, Taniguchi Y, Fukumoto S, Nangaku M, Makita N, Hoshi K, Nakano K, Ito N. Effect of conventional treatment on dental complications and ectopic ossifications among 30 adults with XLH. J Clin Endocrinol Metab. 2022 Dec 16:dgac732. doi: 10.1210/clinem/dgac732. Epub ahead of print. PMID: 36524341.
  • Hoshino Y, Hidaka N, Kato H, Koga M, Taniguchi Y, Kobayashi H, Nangaku M, Makita N, Ito N. Incidence of ossification of the spinal ligaments in acromegaly patients. Bone Rep. 2022 Oct 17;17:101628. doi: 10.1016/j.bonr.2022.101628. PMID: 36299702; PMCID: PMC9589022.
  • Ashrafzadeh-Kian SL, Ito N, Srivastava T, Garg U, Kato H, Algeciras-Schimnich A, Bornhorst JA. The Effect of Burosumab on Intact and C-terminal FGF23 Measurements. Clin Endocrinol (Oxf). 2022 Oct 20. doi: 10.1111/cen.14832. Epub ahead of print. PMID: 36263608.
  • Kato H, Hoshino Y, Hidaka N, Ito N, Makita N, Nangaku M, Inoue K. Machine Learning-Based Prediction of Elevated PTH Levels Among the US General Population. J Clin Endocrinol Metab. 2022 Sep 19:dgac544. doi: 10.1210/clinem/dgac544. Epub ahead of print. PMID: 36125184.
  • Brandi ML, Jan de Beur S, Briot K, Carpenter T, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Imel EA, Ing SW, Insogna K, Ito N, Javaid K, Kamenicky P, Keen R, Kubota T, Lachmann RH, Perwad F, Pitukcheewanont P, Portale A, Ralston SH, Tanaka H, Weber TJ, Yoo HW, Sun W, Williams A, Nixon A, Takeuchi Y. Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study. Calcif Tissue Int. 2022 Aug 4. doi: 10.1007/s00223-022-01006-7. Epub ahead of print. PMID: 35927518.
  • Hidaka N, Koga M, Kimura S, Hoshino Y, Kato H, Kinoshita Y, Makita N, Nangaku M, Horiguchi K, Furukawa Y, Ohnaka K, Inagaki K, Nakagawa A, Suzuki A, Takeuchi Y, Fukumoto S, Nakatani F, Ito N. Clinical Challenges in Diagnosis, Tumor Localization and Treatment of Tumor-Induced Osteomalacia: Outcome of a Retrospective Surveillance. J Bone Miner Res. 2022 Jun 11. doi: 10.1002/jbmr.4620. Epub ahead of print. PMID: 35690913.
  • Hofstaetter JG, Atkins GJ, Kato H, Kogawa M, Blouin S, Misof BM, Roschger P, Evdokiou A, Yang D, Solomon LB, Findlay DM, Ito N. A Mild Case of Autosomal Recessive Osteopetrosis Masquerading as the Dominant Form Involving Homozygous Deep Intronic Variations in the CLCN7 Gene. Calcif Tissue Int. 2022 May 26. doi: 10.1007/s00223-022-00988-8. Epub ahead of print. PMID: 35618777.
  • Kato H, Ansh AJ, Lester ER, Kinoshita Y, Hidaka N, Hoshino Y, Koga M, Taniguchi Y, Uchida T, Yamaguchi H, Niida Y, Nakazato M, Nangaku M, Makita N, Takamura T, Saito T, Braddock DT, Ito N. Identification of ENPP1 haploinsufficiency in patients with diffuse idiopathic skeletal hyperostosis and early-onset osteoporosis. J Bone Miner Res. 2022 Mar 26. doi: 10.1002/jbmr.4550. Epub ahead of print. PMID: 35340077.
  • Kato H, Hidaka N, Koga M, Kinoshita Y, Makita N, Nangaku M, Ito N. Radiological evaluation of pseudofracture after the administration of asfotase alfa in an adult with benign prenatal hypophosphatasia: A case report. Bone Rep. 2021 Dec 29;16:101163. doi: 10.1016/j.bonr.2021.101163. PMID: 35024386; PMCID: PMC8728307.
  • Hidaka N, Kato H, Koga M, Katsura M, Oyama Y, Kinoshita Y, Fukumoto S, Makita N, Nangaku M, Ito N. Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption. Bone Rep. 2021 Dec 15:101144 doi: 10.1016/j.bonr.2021.101144
  • Kato H, Hidaka N, Koga M, Kinoshita Y, Nangaku M, Makita N, Ito N. Altered Thyroid Function Tests Observed in Hypophosphatasia Patients Treated with Asfotase Alfa. Int J Endocrinol. 2021 Oct 28;2021:5492267. doi: 10.1155/2021/5492267. PMID: 34745256; PMCID: PMC8568557.
  • Ito N, Kang HG, Nishida Y, Evins A, Skrinar A, Cheong HI. Burden of disease of X-linked hypophosphatemia in Japanese and Korean patients: a cross-sectional survey. Endocr J. 2021 Nov 2. doi: 10.1507/endocrj.EJ21-0386. Epub ahead of print. PMID: 34732603.
  • Kato H, Ito N, Makita N, Nangaku M, Leung AM, Inoue K. Association of Serum Parathyroid Hormone Levels with All-cause and Cause-specific Mortality Among US Adults. Endocr Pract. 2021 Sep 23:S1530-891X(21)01233-7. doi: 10.1016/j.eprac.2021.09.005. Online ahead of print.PMID: 34563702
  • Briot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Ing S, Insogna K, Ito N, Jan de Beur S, Javaid MK, Kamenicky P, Keen R, Kubota T, Lachmann RH, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Nixon A, Nixon M, Sun W, Williams A, Imel EA. Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open. 2021 Sep;7(3):e001714. doi: 10.1136/rmdopen-2021-001714.PMID: 34548383
  • Koga M, Kinoshita Y, Kato H, Kobayashi H, Shinoda Y, Nangaku M, Makita N, Dahir KM, Ito N. Massive calcification around large joints in a patient subsequently diagnosed with adult-onset hypophosphatasia. Osteoporos Int. 2021 Sep 8. doi: 10.1007/s00198-021-06145-5. Online ahead of print.PMID: 34494146
  • Kato H, Hidaka N, Koga M, Ogawa N, Takahashi S, Miyazaki H, Nangaku M, Makita N, Ito N. Performance evaluation of the new chemiluminescent intact FGF23 assay relative to the existing assay system. J Bone Miner Metab. 2021 Aug 5. doi: 10.1007/s00774-021-01258-7. Online ahead of print.PMID: 34351500
  • Ito N, Kubota T, Kitanaka S, Fujiwara I, Adachi M, Takeuchi Y, Yamagami H, Kimura T, Shinoda T, Minagawa M, Okazaki R, Ozono K, Seino Y, Fukumoto S. Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23. J Bone Miner Metab. 2021 Jul 13. doi: 10.1007/s00774-021-01250-1. Online ahead of print.PMID: 34255195
  • Kinoshita Y, Mohamed FF, Amadeu de Oliveira F, Narisawa S, Miyake K, Foster BL, Millán JL. Gene Therapy Using Adeno-Associated Virus Serotype 8 Encoding TNAP-D10 Improves the Skeletal and Dentoalveolar Phenotypes in Alpl-/- Mice. J Bone Miner Res. 2021 Jun 2. doi: 10.1002/jbmr.4382. Online ahead of print.PMID: 34076297
  • Kato H, Koga M, Kinoshita Y, Taniguchi Y, Kobayashi H, Fukumoto S, Nangaku M, Makita N, Ito N. Incidence of complications in 25 adult patients with X-linked hypophosphatemia. J Clin Endocrinol Metab. 2021 Apr 29:dgab282. doi: 10.1210/clinem/dgab282. Online ahead of print.PMID: 33912912
  • Ito N, Prideaux M, Wijenayaka AR, Yang D, Ormsby RT, Bonewald LF, Atkins GJ. Sclerostin Directly Stimulates Osteocyte Synthesis of Fibroblast Growth Factor-23. Calcif Tissue Int. 2021 Feb 22. doi: 10.1007/s00223-021-00823-6. Online ahead of print. PMID: 33616712
  • Kato H, Koga M, Kobayashi H, Maki H, Ikemura M, Kurokawa M, Nangaku M, Makita N, Ito N. Primary bone adult T cell lymphoma with multiple skeletal lesions and debilitating painful osteolysis: a case report. Osteoporos Int. 2021 May;32(5):1013-1017. doi: 10.1007/s00198-020-05720-6. Epub 2020 Oct 31.PMID: 33128574
  • Imanishi Y, Ito N, Rhee Y, Takeuchi Y, Shin CS, Takahashi Y, Onuma H, Kojima M, Kanematsu M, Kanda H, Seino Y, Fukumoto S. Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia. J Bone Miner Res. 2021 Feb;36(2):262-270. doi: 10.1002/jbmr.4184. Epub 2020 Nov 4.PMID: 32967046
  • Kobayashi H, Makise N, Ito N, Koga M, Zhang L, Ishibashi Y, Ikegami M, Shinoda Y, Akiyama T, Ushiku T, Tanaka S. Surgical margin for phosphaturic mesenchymal tumors in soft tissues: An analysis of the radiological histopathological correlation. J Orthop Sci. 2020 Aug 11:S0949-2658(20)30195-0. doi: 10.1016/j.jos.2020.07.006. Online ahead of print.J Orthop Sci. 2020. PMID: 32798110
  • Kubota T, Fukumoto S, Cheong HI, Michigami T, Namba N, Ito N, Tokunaga S, Gibbs Y, Ozono K. Long-term outcomes for Asian patients with X-linked hypophosphataemia: rationale and design of the SUNFLOWER longitudinal, observational cohort study. BMJ Open. 2020 Jun 29;10(6):e036367. doi: 10.1136/bmjopen-2019-036367. PMID: 32601114
  • Ito N, Fukumoto S. Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23. Calcif Tissue Int. 2021 Jan;108(1):104-115. doi: 10.1007/s00223-020-00659-6. Epub 2020 Jan 22.PMID: 31965220 Review.
  • Kobayashi H, Hirai T, Makise N, Ushiku T, Ito N, Koga M, Ikegami M, Shinoda Y, Akiyama T, Tanaka S.　Reconstruction Using Frozen Autograft for Disseminated Phosphaturic Mesenchymal Tumor of the Humerus after a Pathological Fracture.Case Rep Orthop. 2019 Sep 4;2019:3015675. doi: 10.1155/2019/3015675. eCollection 2019.PMID:31565455
  • Sahoo SK, Kushwaha P, Bharti N, Khedgikar V, Trivedi R, Agrawal V, Ahmad N, Zaidi G, Paul L, Ito N, Bhatia E.　Elevated FGF23 in a patient with hypophosphatemic osteomalacia associated with neurofibromatosis type 1.　Bone. 2019 Dec;129:115055. doi: 10.1016/j.bone.2019.115055. Epub 2019 Aug 30.　PMID:31476437
  • Insogna KL, Rauch F, Kamenický P, Ito N, Kubota T, Nakamura A, Zhang L, Mealiffe M, San Martin J, Portale AA.　Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial.J Bone Miner Res. 2019 Dec;34(12):2183-2191. doi: 10.1002/jbmr.3843. Epub 2019 Oct 1. 　PMID:31369697
  • Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, Crowley R, Jan De Beur S, Eastell R, Imanishi Y, Imel EA, Ing S, Ito N, Javaid M, Kamenicky P, Keen R, Kubota T, Lachmann R, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Zhang L, Theodore-Oklota C, Mealiffe M, San Martin J, Insogna K. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. Calcif Tissue Int. 2019 Sep;105(3):271-284. doi: 10.1007/s00223-019-00568-3. 2019 Jun 4. PMID:31165191
  • Takashi Y, Kosako H, Sawatsubashi S, Kinoshita Y, Ito N, Tsoumpra MK, Nangaku M, Abe M, Matsuhisa M, Kato S, Matsumoto T, Fukumoto S. Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation. Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11418-11427. PMID:31097591
  • Manaka K, Sato J, Kinoshita Y, Ito N, Fujita M, Iiri T, Nangaku M, Makita N. Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience. Endocr J. 2019 Aug 29;66(8):683-689. doi: 10.1507/endocrj.EJ19-0034. Epub 2019 May 16.  PMID:31092749
  • Kobayashi H, Makise N, Ushiku T, Ito N, Koga M, Shinoda Y, Tanaka S. Infiltrative nature of tumor-induced osteomalacia lesions in bone: Correlation between radiological and histopathological features. J Orthop Sci. 2019 Sep;24(5):900-905. doi: 10.1016/j.jos.2019.02.005. Epub 2019 Feb 21.　PMID:30797665
  • Kinoshita Y, Takashi Y, Ito N, Ikegawa S, Mano H, Ushiku T, Fukayama M, Nangaku M, Fukumoto S.　Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO).　Bone Rep. 2018; 31;10:100192. PMID:30627598
  • Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO; AXLES 1 Investigators. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis J Bone Miner Res. 2018; 33: 1383-1393. PMID:29947083
  • Kinoshita Y, Fukumoto S. X-linked hypophosphatemia and FGF23-related hypophosphatemic diseases -Prospect for new treatment. Endocr Rev. 2018; 39 :274-291. PMID:29381780
  • Kobayashi H, Ito N, Akiyama T, Okuma T, Kinoshita Y, Ikegami M, Shinoda Y, Fukumoto S, Tanaka S, Kawano H. Prevalence and clinical outcomes of hip fractures and subchondral insufficiency fractures of the femoral head in patients with tumour-induced osteomalacia. Int Orthop. 2017;　41:　2597-2603.　PMID:28836028
  • Kinoshita Y, Ito N, Makita N, Nangaku M, Fukumoto S.　Changes in bone metabolic parameters following oral calcium supplementation in an adult patient with vitamin D-dependent rickets type 2A.　Endocr J. 2017; 64: 589-596.　PMID:28367941
  • Takashi Y, Kinoshita Y, Ito N, Taguchi M, Takahashi M, Egami N, Tajima S, Nangaku M, Fukumoto S. Tumor-induced Osteomalacia Caused by a Parotid Tumor. Intern Med. 2017; 56: 535-539.
  • Kobayashi H, Akiyama T, Okuma T, Shinoda Y, Oka H, Ito N, Fukumoto S, Tanaka S, Kawano H. Three-dimensional fluoroscopic navigation-assisted surgery for tumors in patients with tumor-induced osteomalacia in the bones. Comput Assist Surg (Abingdon). 2017; 12: 1-14.
  • Takashi Y, Kinoshita Y, Hori M, Ito N, Taguchi M, Fukumoto S. Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy. Endocr Res. 2017; 42: 132-137.
  • Kinoshita Y, Arai M, Ito N, Takashi Y, Makita N, Nangaku M, Shinoda Y, Fukumoto S. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors. Endocr J. 2016; 63: 479-484.
  • Hori M, Kinoshita Y, Taguchi M, Fukumoto S. Phosphate enhances Fgf23 expression through reactive oxygen species in UMR-106 cells. J Bone Miner Metab. 2016; 34: 132-139.
  • Tajima S, Takashi Y, Ito N, Fukumoto S, Fukuyama M. ERG and FLI1 are useful immunohistochemical markers in phosphaturic mesenchymal tumors. Med Mol Morphol. 2016; 49: 203-209.
  • Wijenayaka AR, Yang D, Prideaux M, Ito N, Kogawa M, Anderson PH, Morris HA, Solomon LB, Loots GG, Findlay DM, Atkins GJ. 1α,25-dihydroxyvitamin D3 stimulates human SOST gene expression and sclerostin secretion. Mol Cell Endocrinol 2015; 413: 157-167.
  • Takashi Y, Kinoshita Y, Makita N, Taguchi M, Takahashi K, Nangaku M, Fukumoto S. Rapid Recovery of Hypothalamic-Pituitary Axis after Successful Resection of an ACTH-secreting Neuroendocrine Tumor. Intern Med 2015; 54: 2201-2205.
  • Ito N, Wijenayaka AR, Prideaux M, Kogawa M, Ormsby RT, Evdokiou A, Bonewald LF, Findlay DM, Atkins GJ. Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli. Mol Cell Endocrinol. 2015; 399: 208-218.
  • Nakamura T, Aizawa T, Hoshikawa T, Ozawa H, Ito N, Fukumoto S, Itoi E, Kokubun S.　Tumor-induced osteomalacia caused by phosphaturic mesenchymal tumor of the cervical spine. J Orthop Sci. 2015; 20: 765-771. PMID: 24504987
  • Kinoshita Y, Hori M, Taguchi M, Fukumoto S. Functional analysis of mutant FAM20C in Raine syndrome with FGF23-related hypophosphatemia. Bone. 2014; 67: 145-151.
  • Ito N, Peña AS, Perano S, Atkins GJ, Findlay DM, Couper JJ. First Australian report of vitamin D-dependent rickets type I. Med J Aust. 2014; 201: 420-421.
  • Kinoshita Y, Hori M, Taguchi M, Watanabe S, Fukumoto S. Functional activities of mutant calcium-sensing receptors determine clinical presentations in patients with autosomal dominant hypocalcemia. J Clin Endocrinol Metab. 2014; 99: E363-368.
  • Ito N, Findlay DM, Atkins GJ. Osteocyte Communication with the Kidney Via the Production of FGF23: Remote Control of Phosphate Homeostasis. Clin Rev Bone Miner Metab. 2014; 12: 44-58.
  • Ito N, Findlay DM, Anderson PH, Bonewald LF, Atkins GJ. Extracellular phosphate modulates the effect of 1α,25-dihydroxy vitamin D(3) (1,25D) on osteocyte like cells. J Steroid Biochem Mol Biol. 2013; 136: 183-186.
  • Kinoshita Y, Saito T, Shimizu Y, Hori M, Taguchi M, Igarashi T, Fukumoto S, Fujita T. Mutational analysis of patients with FGF23-related hypophosphatemic rickets. Eur J Endocrinol. 2012; 167: 165-172.
  • Kinoshita Y, Fujii H, Takeshita A, Taguchi M, Miyakawa M, Oyama K, Yamada S, Takeuchi Y. Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic {beta}-cell function is preserved. Eur J Endocrinol. 2011; 164: 467-473.
  • Ito N, Shimizu Y, Suzuki H, Saito T, Okamoto T, Hori M, Akahane M, Fukumoto S, Fujita T. Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia. J Intern Med. 2010; 268: 390-394.
  • Sakurai-Chin C, Ito N, Taguchi M, Miyakawa M, Takeshita A, Takeuchi Y. Hypoglycemic coma in a patient with anorexia nervosa coincident with acute exacerbation of liver injury induced by oral intake of nutrients. Intern Med. 2010; 49: 1553-1556
  • Saito T, Fukumoto S, Ito N, Suzuki H, Igarashi T, Fujita T. A novel mutation in the GATA3 gene of a Japanese patient with PTH-deficient hypoparathyroidism. J Bone Miner Metab. 2009; 27: 386-389.
  • Saito T, Nishii Y, Yasuda T, Ito N, Suzuki H, Igarashi T, Fukumoto S, Fujita T. Familial hypophosphatemic rickets caused by a large deletion in PHEX gene. Eur J Endocrinol. 2009; 161: 647-651.
  • Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009; 45: 814-816.
  • Kinoshita Y, Masuoka K, Miyakoshi S, Taniguchi S, Takeuchi Y. Vitamin D insufficiency underlies unexpected hypocalcemia following high dose glucocorticoid therapy. Bone. 2008; 42: 226-268.
  • Nasu T, Kurisu S, Matsuno S, Tatsumi K, Kakimoto T, Kobayashi M, Nakano Y, Wakasaki H, Furuta H, Nishi M, Sasaki H, Suzuki H, Ito N, Fukumoto S, Nanjo K. Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23. Intern Med. 2008; 47: 957-961.
  • Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, Yamashita T, Fujita T. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab. 2007; 25: 419-422.
  • Kawarazaki H, Shibagaki Y, Shimizu H, Kawarazaki W, Ito N, Ishikawa A, Fukumoto S, Fujita T. Persistent high level of fibroblast growth factor 23 as a cause of post-renal transplant hypophosphatemia. Clin Exp Nephrol. 2007; 11: 255-257.
  • Ito N, Fukumoto S, Taguchi M, Takeshita A, Takeuchi Y, Yamada S, Fujita T. Fibroblast growth factor (FGF)23 in patients with acromegaly. Endocr J. 2007; 54: 481-484.
  • Frishberg Y, Ito N, Rinat C, Yamazaki Y, Feinstein S, Urakawa I, Navon-Elkan P, Becker-Cohen R, Yamashita T, Araya K, Igarashi T, Fujita T, Fukumoto S. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res. 2007; 22: 235-242.
  • Ito N, Fukumoto S, Takeuchi Y, Yasuda T, Hasegawa Y, Takemoto F, Tajima T, Dobashi K, Yamazaki Y, Yamashita T, Fujita T. Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab. 2005; 23: 435-440.
  • Kinoshita Y, Taguchi M, Takeshita A, Miura D, Tomikawa S, Takeuchi Y. 1,25-dihydroxyvitamin D suppresses circulating levels of parathyroid hormone in a patient with primary hyperparathyroidism and coexistent sarcoidosis. J Clin Endocrinol Metab. 2005; 90:6727-6731.
  • Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, Ito N, Yoshii N, Yamazaki Y, Yamashita T, Silver J, Igarashi T, Fujita T. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab. 2005; 90: 5523-5527.

TOP▲